Alavi M, et al. - Researchers sought to assess cause-specific mortality trends including liver-related mortality among people with a hepatitis B virus (HBV) and hepatitis C virus (HCV) notification in New South Wales, Australia. They noted declining HBV-related liver mortality rates and stable burden, which might be related to improved antiviral therapy efficacy and uptake. In contrast, there appeared limited impact of interferon-containing HCV treatment programs on liver-related mortality individual-level risk and population-level burden. HBV/HCV public health interventions that incorporate increased antiviral therapy uptake and action on health risk behaviors seemed to be significant.